Translational Partnerships Award: 3 Year Renewal

The University of Cambridge is expanding its programme that helps researchers turn lab discoveries into real-world products and treatments. This matters because many promising research findings never leave the university. Academics often lack the business knowledge, industry connections, or legal support needed to develop a drug, diagnostic tool, or medical device. The programme—a renewal of the iTPA—provides dedicated staff, funding, and guidance to bridge that gap. It specifically aims to include early-career researchers and projects from a wider range of scientific fields, not just biomedicine. If successful, the programme could accelerate the journey from fundamental science to tangible benefits for human health and wellbeing. This might mean faster development of new therapies, more efficient medical devices, or innovations in climate and environment technologies. The university aims to become the UK’s leading translational environment by 2025, with measurable impact on health by 2030. The goal is to make this support sustainable beyond the period of Wellcome’s funding, so the infrastructure for turning research into impact outlasts the grant itself.